Tue Oct 07 08:30:00 UTC 2025: Here’s a summary of the text and a news article based on it:
**Summary:**
McKesson, a healthcare company focused on improving care in all settings, is partnering with the non-profit organization Angels for Change (A4C) to combat drug shortages, particularly in cancer treatment. This partnership includes initiatives like Project GOLD, which aims to create a buffer stock of essential chemotherapy drugs. The collaboration extends beyond logistics, involving advocacy for systemic change and support for patients navigating drug shortages. McKesson also focuses on improving access to medication through various business endeavors, and aims for impact in other healthcare areas, like pharmacies and health systems.
**News Article:**
**McKesson Partners with Angels for Change to Tackle Critical Drug Shortages**
**[City, State] –** Healthcare giant McKesson is intensifying its efforts to combat critical drug shortages through a strategic partnership with Angels for Change (A4C), a non-profit organization dedicated to preventing drug shortages and ensuring patient access to life-saving medications. The collaboration is particularly focused on addressing shortages of essential cancer treatments.
The partnership gained momentum after McKesson’s involvement with Laura Bray’s daughter, Abby, who battled leukemia and faced multiple drug shortages. Bray, inspired by the challenges her daughter faced, founded A4C to advocate for patients and create solutions to prevent drug shortages.
“I was a mom desperate for medicine for my daughter and McKesson answered the call,” Bray recalls.
One of the key initiatives resulting from this partnership is Project GOLD (Generic Oncology Lifesaving Drugs), a first-of-its-kind program designed to create an emergency buffer stock of six essential chemotherapy drugs prone to shortages. This reserve of medications will be managed within McKesson’s distribution network, ensuring rapid availability for patients in need.
“We put the patient at the center of everything we do,” said Kirk Kaminsky, executive vice president, group president of the North American Pharmaceutical Services business at McKesson. “That’s why we’re building a reliable, resilient and sustainable supply chain to help address drug shortages holistically.”
McKesson and A4C are also collaborating on advocacy efforts, pushing for systemic changes at White House forums and through industry conferences. These efforts are making a tangible difference, with A4C helping patients access over 750,000 life-saving treatments since its inception.
Beyond Project GOLD, McKesson highlights its broader commitment to healthcare, including pharmaceutical distribution, pharmacy financial support, cancer care support, biopharma services, cost reduction solutions, and overall aims for community health impact.
First Piper 